Sébastien Riviere
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sébastien Riviere has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Olivier Fain
Sorbonne Université Service de médecine interne, AP-HP, Hôpital Saint Antoine, Paris, France
2 shared publications - Achille Aouba
Department of Internal Medicine, Caen University Hospital, Caen, France
1 shared publication - Alain Le Quellec
Service de Médecine Interne, CHU de Montpellier, Montpellier, Occitanie, France
1 shared publication - Alain Lescoat
Department of Internal Medicine and Clinical Immunology, Rennes University Hospital
1 shared publication - Alexis F Guédon
Institut Pierre Louis d'Epidemiologie et de Sante Publique, Paris, Île-de-France, France
1 shared publication - Anne-Laure Fauchais
Department of Internal Medicine, Limoges University Hospital, Limoges, France
1 shared publication
Latest Publications
- Open Access
Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis
Background and aims Systemic sclerosis (SSc) is an autoimmune connective disease characterised by excessive extracellular matrix deposition and widespread skin and internal organ fibrosis including various cardiac manifestations. Heart involvement is one of the leading causes of death among patients with SSc. In this study, we aimed to assess the effect of various vasodilator treatments. Methods We used data from a national multicentric prospective study using the French SSc national database. We estimated the average treatment effect (ATE) of sildenafil, bosentan, angiotensin-converting enzyme (ACE) inhibitors and iloprost on diastolic dysfunction, altered ejection fraction Results We included 1048 patients with available data regarding treatment. Regarding sildenafil analyses, the ATE on diastolic dysfunction at 3 years was −2.83% (95% CI −4.06; −1.60, pConclusions Using causal methods, our study is the first and largest suggesting that sildenafil might have benefits among SSc patients regarding diastolic dysfunction and altered ejection fraction occurrence. However, further studies assessing the effect of vasodilators on heart-related outcome among SSc patients are needed to confirm those exploratory results.
Open AccessVasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis
Background and aims Systemic sclerosis (SSc) is an autoimmune connective disease characterised by excessive extracellular matrix deposition and widespread skin and internal organ fibrosis including various cardiac manifestations. Heart involvement is one of the leading causes of death among patients with SSc. In this study, we aimed to assess the effect of various vasodilator treatments. Methods We used data from a national multicentric prospective study using the French SSc national database. We estimated the average treatment effect (ATE) of sildenafil, bosentan, angiotensin-converting enzyme (ACE) inhibitors and iloprost on diastolic dysfunction, altered ejection fraction Results We included 1048 patients with available data regarding treatment. Regarding sildenafil analyses, the ATE on diastolic dysfunction at 3 years was −2.83% (95% CI −4.06; −1.60, pConclusions Using causal methods, our study is the first and largest suggesting that sildenafil might have benefits among SSc patients regarding diastolic dysfunction and altered ejection fraction occurrence. However, further studies assessing the effect of vasodilators on heart-related outcome among SSc patients are needed to confirm those exploratory results.
- 9 December 2013
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 43 (2) , 170-171
Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis
Systemic sclerosis (SSc) is a connective tissue disease characterized by sclerotic changes in the skin and organs. Interstitial lung disease (ILD) occurs in more than half of patients with SSc and ...
- 9 December 2013
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 43 (2) , 170-171
Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis
Systemic sclerosis (SSc) is a connective tissue disease characterized by sclerotic changes in the skin and organs. Interstitial lung disease (ILD) occurs in more than half of patients with SSc and ...